Auph short interest.

Short interest is the volume of POINT Biopharma Global shares that have been sold short but have not yet been covered or closed out. As of October 31st, traders have sold 4,390,000 shares of PNT short. 5.09% of POINT Biopharma Global's shares are currently sold short. Learn More on POINT Biopharma Global's current short interest.May 11, 2023 · The largest shareholder of Aurinia Pharmaceuticals ( NASDAQ: AUPH) said it plans to withholder support for seven board members at the company's upcoming annual meeting. Iljin SNT, which has a 6.1% ... Aurinia Pharmaceuticals Stock (NASDAQ:AUPH), Short Interest Report. Short interest for Aurinia Pharmaceuticals gives investors a sense of the degree to …Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH – Get Free Report) (TSE:AUP) was the target of a large increase in short interest in September. As of September 15th, there was short interest totalling ...View the latest Aurinia Pharmaceuticals Inc. (AUPH) stock price, news, historical charts, analyst ratings and financial information from WSJ.

This short interest tracker provides a variety of short interest related data, sourced from a variety of partners. The data is organized by …Short Interest. Percentage of Shares Shorted 11.97% of the outstanding shares of Aurinia Pharmaceuticals have been sold short. Short Interest Ratio / Days to …

Affimed saw a decline in short interest in the month of November. As of November 15th, there was short interest totaling 1,640,000 shares, a decline of 24.1% from the October 31st total of 2,160,000 shares. Based on an average daily volume of 562,700 shares, the short-interest ratio is currently 2.9 days. View Affimed's Short Interest.

Nasdaq provides market information on after hours trading daily from 4:15 p.m. ET to 3:30 p.m. ET on the following day. $175.49 -3.58 -2%. NVIDIA Corporation Common Stock. $422.39 -12.81 -2.94% ...AUPH | Aurinia Pharmaceuticals short interest and earnings date annual report Jul, 2023 Mailing Address #1203-4464 MARKHAM STREET VICTORIA BC A1 V8Z 7X8. Business Address #1203-4464 MARKHAM STREET VICTORIA BC A1 V8Z 7X8 250-708-4272. SIC: 2834 - PHARMACEUTICAL PREPARATIONS. State location: A1 | State of Inc.: A0 | …E131: 2024 Fantasy President picks, debt ceiling agreement, Dollar dominance & moreWebAug 3, 2023 · Some thoughts on AUPH: 1. As cited, AUPH reported Lupkynis sales +46% YOY, +20% over Q1, and raised full year guidance to $150 million - $160 million, but admittedly is only scratching the surface ... Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) has seen a decrease in hedge fund interest in recent months. Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) was in 24 hedge funds' portfolios at the end of ...

Canadian biotech Aurinia Pharmaceuticals (AUPH) lost ~22% pre-market Thursday even after announcing better-than-expected financials for Q3 2022 as the company lowered its full-year...

The SEC requires all publicly traded companies, foreign and domestic, to disclose financial condition, operating results, management compensation, and other areas of their business on a regular ...

Rumors are that they will pay at least 40 till 44 dollar. Earnings are coming sooner at the 3rd of November. But there is also a high SI. Some buying…In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in AUPH / Aurinia Pharmaceuticals Inc. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. @PITX3 not really great short squeeze potential, more like short caress. 11% of float takes 5 - 6 days to cover. From mid-April to mid-May the short position decreased by 2M down to 15.5M, 11% of ...In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in AUPH / Aurinia Pharmaceuticals Inc. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price.Short Interest. Most Shorted. Largest Increase. Largest Decrease. ... The analyst firm set a price target for $15.00 expecting AUPH to rise to within 12 months (a possible 67.41% …

@HowIgraph @AverygraceMoore @theoriginalspa3 decreased short interest was not real good anyway as the shorts provide support. plus, even RLYP short interest rose into a buyout; it was near 20% if i remember correctly. the fact that AUPH short interest is so low actually has been baffling, but it may be that they use optionsBiocept, Inc. (NASDAQ:BIOC – Get Free Report) was the target of a significant decline in short interest in July. As of July 15th, there was short interest totalling 26,500 shares, a decline of 6.7% from the June 30th total of 28,400 shares. Approximately 1.8% of the company’s stock are sold short. Based on an average […]WebFind out why interest in selling AUPH stock has not subsided in some quarters. ... @PITX3 not really great short squeeze potential, more like short caress. 11% of float takes 5 ...2023-03-14 Short sale volume (not short interest) for $AUPH is 32%. http://shortvolumes.com/?t=AUPH $XLV 48% $AEZS 50% $REGN 54%. 16 Mar 2023 00:36:01WebOct 29, 2021 · Zhanna Hapanovich/iStock via Getty Images. Aurinia Pharmaceuticals (NASDAQ: AUPH) may be worth $45-$53/share in a possible sale and may see interest from other pharma cos. besides Bristol Myers ... The setup was perfect (IMO) with more than 21% Short Interest, a Put/Call ratio of 0.25 (Dec-2023) and a strong earnings + guidance from a grossly oversold position. Long term Bullish, but I will be waiting for the $3.29 gap fill most likely to re-build, unless the Company can formalize a plan to be NASDAQ compliant in short-order. 1969: CARVAurinia Pharma (AUPH) is scheduled to announce Q2 earnings results on Thursday, August 3rd, before market open.The consensus EPS Estimate is -$0.18 (+28.0% Y/Y) and the consensus...

Short Float / Ratio: 13.17% / 8.88: Perf Quarter-4.23%: Sales: 158.85M: P/S: 8.19: EPS this Y: 31.36%: Inst Trans: 9.16%: Short Interest: 17.19M: Perf Half Y-5.03%: Book/sh: 2.73: P/B: 3.32: EPS next Y: 29.71%: ROA-14.80%: Target Price: 13.21: Perf Year: 76.61%: Cash/sh: 2.35: P/C: 3.85: EPS next 5Y-ROE-18.94%: 52W Range: 4.07 - 12.43: Perf YTD ... The SPDR S&P Biotech ETF, one of the largest U.S. biotech ETFs, has a short interest percent of float of 57.7%, according to data from S3 Partners.

About Latest Pre-Market Trades. Nasdaq provides market information before market opens daily from 4:15 A.M. ET to 7:30 A.M. ET on the following day.As women age, their hair tends to become thinner and more fragile. Many older women find that long hair is difficult to maintain, and it can make them look older than they really are. Short haircuts, on the other hand, can be a great option...The largest shareholder of Aurinia Pharmaceuticals ( NASDAQ: AUPH) said it plans to withholder support for seven board members at the company's upcoming annual meeting. Iljin SNT, which has a 6.1% ...In Leo Tolstoy’s short story “What Men Live By,” the angel Michael learns that people dwell best when in love and that they do not always know what is in their best interests. Michael also learns that people live best by loving others and n...Aug 2, 2023 · Aurinia Pharma (AUPH) is scheduled to announce Q2 earnings results on Thursday, August 3rd, before market open.The consensus EPS Estimate is -$0.18 (+28.0% Y/Y) and the consensus... Business, Economics, and Finance. GameStop Moderna Pfizer Johnson & Johnson AstraZeneca Walgreens Best Buy Novavax SpaceX Tesla. Crypto

Zhanna Hapanovich/iStock via Getty Images. Aurinia Pharmaceuticals (NASDAQ: AUPH) may be worth $45-$53/share in a possible sale and may see interest from other pharma cos. besides Bristol Myers ...

Auph only had 1 month of sales last quarter, due to insurance companys taking 20 to 50 days to approve each patient...thats the reason for sales short fall Reply Like (7) d

In Leo Tolstoy’s short story “What Men Live By,” the angel Michael learns that people dwell best when in love and that they do not always know what is in their best interests. Michael also learns that people live best by loving others and n...The average one-year price target for AUPH / Aurinia Pharmaceuticals Inc is $14.28. The forecasts range from a low of $12.12 to a high of $15.75. A stock’s price target is the price at which analysts consider it fairly valued with respect to its projected earnings and historical earnings. Analysts typically set price targets that correspond ... Market Capitalization. $1.24 billion. P/E Ratio. N/A. Dividend Yield. N/A. Price Target. $14.00. Stock Analysis Analyst Forecasts Chart Competitors Earnings Financials Headlines Insider Trades Options Chain Ownership SEC Filings Short Interest Social Media.Oct 29, 2021 · Zhanna Hapanovich/iStock via Getty Images. Aurinia Pharmaceuticals (NASDAQ: AUPH) may be worth $45-$53/share in a possible sale and may see interest from other pharma cos. besides Bristol Myers ... The SPDR S&P Biotech ETF, one of the largest U.S. biotech ETFs, has a short interest percent of float of 57.7%, according to data from S3 Partners.Aurinia Pharmaceuticals Inc Ordinary Shares (AUPH) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.The SPDR S&P Biotech ETF, one of the largest U.S. biotech ETFs, has a short interest percent of float of 57.7%, according to data from S3 Partners.Sep 27, 2023 · Aurinia Pharmaceuticals posted its second quarter numbers on August 3rd. The company posted a GAAP loss of 8 cents a share, more than a dime a share better than expectations. Revenues rose 47% on ... A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. DAWN shares currently have a short interest ratio of 15.0. Learn More on Day One Biopharmaceuticals's short interest ratio.Aurinia ( AUPH) shares have climbed ~59.7% in the year so far despite a ~2% decline over the past 30 days. The stock has added ~5.8% in the post-market with ~1.5M shares changing hands compared to ...

Aurinia Pharmaceuticals (AUPH) Short Interest. Company Profile Short interest 3 months. Data from FINRA. Short interest. Days to cover, using 30-day avg volume. Short ratio, using same-day volume. Volume. Short volume. Total volume. Stock price. Short ownership 3 …To find anything from restaurants to clothing stores and auto repair shops in your area, just search Yelp.com. Though Yelp features information for businesses all around the world, you can narrow your search results down to a radius as shor...Aurinia Pharma (AUPH) is scheduled to announce Q2 earnings results on Thursday, August 3rd, before market open.The consensus EPS Estimate is -$0.18 (+28.0% Y/Y) and the consensus...The average of price targets set by Wall Street analysts indicates a potential upside of 46.1% in Aurinia (AUPH). While the effectiveness of this highly sought-after metric is questionable, the ...Instagram:https://instagram. back of 2009 pennywhat is the best options trading platformstock twits pltrge pension Nov 21, 2023 · Aurinia Pharmaceuticals (AUPH) Short Interest Ratio & Short Volume $8.85 -0.39 (-4.22%) (As of 03:22 PM ET) Compare Today's Range $8.77 $10.05 50-Day Range $7.13 $9.24 52-Week Range $4.07 $12.43 Volume 6.25 million shs Average Volume 2.60 million shs Market Capitalization $1.27 billion P/E Ratio N/A Dividend Yield N/A Price Target $14.00 best aerospace stocksschwab high dividend etf TRKA Update - Nothing has changed with TRKA still sitting at well over 120% short interest. When in doubt just zoom out. This drop is expected after the last run-ups and the heavy shorting. Don't let them scare you off they are …That beat AUPH stock analysts' estimate for $22 million, according to FactSet. Per-share losses were 25 cents, narrower than expectations for 27 cents. Still, AUPH stock fell to its lowest point ...Web one dollar coins 1979 Aurinia Pharmaceuticals ( NASDAQ: AUPH) has been on a roll this year since their second quarter earnings in August. The stock jumped from $10 to over $30, buoyed by strong uptake of voclosporin ...Aurinia Pharmaceuticals (NASDAQ:NASDAQ: AUPH) received U.S. marketing approval for Lupkynis, a treatment for lupus nephritis [LN] , on Friday, Jan 22, 2021. The following Monday the share price ...Jan 5, 2023 · AUPH has multiple downside risks that investors need to consider when managing their position. First, Aurinia is still recording losses and reported a net loss of $82.1M for the first three ...